ProMIS Neurosciences to present overview from PRECISE-AD trial

ProMIS Neurosciences (PMN) announced it has been invited to present an overview of its ongoing PRECISE-AD trial in Alzheimer’s Disease and its proprietary Discovery Platform, EpiSelectTM, at the Alzheimer’s Association International Conference 2025, AAIC, taking place in Toronto, Canada from July 27-31, 2025. “We are pleased to share further details of our ongoing Phase 1b PRECISE-AD clinical trial evaluating PMN310, our novel therapeutic candidate for Alzheimer’s disease,” said Dr. Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences. “PRECISE-AD was intentionally designed with a robust framework to assess both the safety and potential signs of efficacy of PMN310. PMN310 is designed to selectively target toxic amyloid-beta oligomers, which are considered a primary driver of Alzheimer’s disease, while aiming to reduce the risk of safety issues observed with other therapies.”